Loading...
XNASSYBX
Market cap16mUSD
Dec 31, Last price  
1.40USD
1D
0.00%
1Q
-8.04%
Jan 2017
-99.26%
IPO
-99.81%
Name

Synlogic Inc

Chart & Performance

D1W1MN
XNAS:SYBX chart
P/E
—
P/S
4.86
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
32.50%
Rev. gr., 5y
5.99%
Revenues
3m
+185.68%
0000444,0002,444,0002,520,0002,224,000545,0001,754,0001,180,0003,371,000
Net income
-57m
L-11.70%
-3,658,000-6,436,000-15,834,000-24,983,000-26,268,000-40,377,000-48,435,000-48,671,000-56,537,000-58,118,000-64,875,000-57,282,000
CFO
-52m
L-9.27%
-4,520,000-6,496,000-13,970,000-21,135,000-24,805,000-31,055,000-42,470,000-75,468,000-39,553,000-52,198,000-56,888,000-51,614,000
Earnings
Mar 17, 2025

Profile

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
URL
https://www.synlogictx.com/
IPO date
Sep 30, 2015
Employees
72
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,371
185.68%
1,180
-32.73%
Cost of revenue
58,532
74,268
Unusual Expense (Income)
NOPBT
(55,161)
(73,088)
NOPBT Margin
Operating Taxes
14
(1,272)
Tax Rate
NOPAT
(55,175)
(71,816)
Net income
(57,282)
-11.70%
(64,875)
11.63%
Dividends
Dividend yield
Proceeds from repurchase of equity
20,832
(2,225)
BB yield
-83.22%
4.08%
Debt
Debt current
9,568
4,165
Long-term debt
29,766
36,431
Deferred revenue
Other long-term liabilities
Net debt
(8,412)
(38,130)
Cash flow
Cash from operating activities
(51,614)
(56,888)
CAPEX
(214)
(728)
Cash from investing activities
38,769
58,351
Cash from financing activities
20,944
(2,040)
FCF
(51,201)
(84,407)
Balance
Cash
47,746
77,629
Long term investments
1,097
Excess cash
47,577
78,667
Stockholders' equity
(414,285)
(357,109)
Invested Capital
478,999
460,017
ROIC
ROCE
EV
Common stock shares outstanding
6,502
4,782
Price
3.85
-66.23%
11.40
-68.60%
Market cap
25,034
-54.08%
54,511
-59.29%
EV
16,622
16,381
EBITDA
(53,203)
(70,568)
EV/EBITDA
Interest
1,000
2
Interest/NOPBT